Skip to main content

Neuroendocrine Tumors

Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome from the XERMELO Patient Registry

A Population-Based Analysis of Risk for Cancer-Specific Death in Patients with NETs

Multicenter Analysis of Treatment Outcomes for Well-Differentiated Grade 3 NETs

Prognostic Factor Analysis in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms

Pilot Study of XmAb18087, an SSTR2 × CD3 Bispecific Antibody, in Advanced NETs

ATLANT Study Results of Lanreotide Autogel + Temozolomide Combination Therapy in Progressive Thoracic NETs

Lanreotide as Maintenance Therapy After First-Line Treatment in Patients with Nonresectable Duodeno-Pancreatic NETs

Comparative Analysis of Octreotide Long-Acting Release versus Lanreotide in Gastroenteropancreatic NETs

The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations and Persistence Rates

177Lu-Octreotate-PRRT + Temozolomide/Capecitabine in Pancreas and Updated Midgut NETs

1
2
3
4

Page 2 of 4
Results 11 - 20 of 31